Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from TuHURA Biosciences ( (HURA) ).
TuHURA Biosciences, Inc. entered into a Secured Promissory Note and Loan Agreement with the Matthew Nachtrab Revocable Trust, initially securing a loan of $1.5 million with a total potential of $3.0 million. On December 2, 2025, the agreement was amended to extend the loan availability period and adjust the warrants issuable to the lender. Following this amendment, TuHURA borrowed an additional $1.5 million, reaching the full $3.0 million loan capacity, and issued warrants for 234,783 shares of common stock.
The most recent analyst rating on (HURA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
Average Trading Volume: 197,065
Technical Sentiment Signal: Sell
Current Market Cap: $101.5M
For an in-depth examination of HURA stock, go to TipRanks’ Overview page.